Merrill reiterates Alizyme at buy

Alizyme was reiterated by Merrill Lynch analyst Erica Whittaker at a buy rating at a price objective of 215p as the company's fundamentals remain strong despite recent declines. The analyst believes Alizyme is on track for a lucrative partnering deal on its cetilistat obesity drug late this year or early next year. Shares of the Cambridge, U.K.-based drug development company were down 1p, or 0.86%, at 115p on volume of 4,241,171 shares versus the three-month running average of 955,939 shares. (London: AZM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.